Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of Repotrectinib in Pediatric Patients

Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced initiation of a Phase 1/2 clinical study of its lead drug candidate

Benzinga · 11/12/2019 13:30

Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced initiation of a Phase 1/2 clinical study of its lead drug candidate repotrectinib in pediatric patients with ALK-, NTRK- and ROS1-positive solid tumors.